Optimizing Multiple Sclerosis Care in the General Neurology Setting Newer Monoclonal Antibodies

Target Audience
General neurology physicians, PAs, nurse practitioners, nurses, and other healthcare professionals involved in the treatment of patients with MS.

Program Overview
Dr. James Bowen and Dr. Sally Harris review and discuss the newer monoclonal antibodies, ocrelizumab and ofatumumab.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Review the efficacy and safety data for newer MS therapies to facilitate evidence-based care
Identify pre-treatment requirements or recommendations for newer MS therapies
Develop individualized treatment plans that consider appropriate and safe use of newer therapies
FApply effective team-based strategies that include communication with MS specialists to promote optimal patient outcomes